Business Context and Reporting Period
This Form 8-K Current Report was filed by Dermata Therapeutics, Inc. on July 28, 2023, with the report date of August 3, 2023. The filing discloses a change in the company's independent registered public accountant and reports on matters submitted to a vote of security holders at the 2023 Annual Meeting of Stockholders held on August 3, 2023.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses on corporate governance and accounting firm changes rather than financial performance data.
Material Changes
- Change in Certifying Accountant: Mayer Hoffman McCann P.C. (MHM) informed the company on July 28, 2023, that it would not stand for re-appointment for the fiscal year ending December 31, 2024. MHM will cease serving as the independent auditor upon the earliest of the completion of the 2023 Form 10-K, the appointment of a new firm, or April 1, 2024.
- Going Concern Qualification: MHM's audit reports for the fiscal years ended December 31, 2021, and 2022, included a "going concern" explanatory paragraph. No other adverse opinions, disclaimers, or qualifications were noted.
- Equity Plan Amendment: Stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan, increasing the authorized shares for issuance by 513,150 to a total of 629,069 shares.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or management commentary on future outlook. The primary risk disclosed is the departure of the independent auditor, which necessitates the selection of a new firm. The Audit Committee has initiated a process to select a replacement. There were no disagreements with MHM regarding accounting principles, practices, or auditing scope during the periods covered.
Investor Verification Checklist
- Verify the timeline for the appointment of a new independent registered public accounting firm.
- Review the "going concern" explanatory paragraphs in the 2021 and 2022 audited financial statements to understand the specific liquidity or operational concerns cited.
- Confirm the final voting results for the election of Class II directors (David Hale, Steven Mento, and Brittany Bradrick), noting the significant number of votes cast against Hale and Mento.
- Monitor subsequent filings for the engagement letter of the new audit firm and the filing of the 2023 Form 10-K.